ClinicalTrials.gg
CompletedNCT03317002FLAVOURUpdated Jun 30, 2021Results posted

AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

A Phase 2 interventional study of AZD5718 and AZD5718 in Coronary Artery Disease, sponsored by AstraZeneca. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-30.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Coronary Artery Disease by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Coronary Artery Disease · AstraZeneca.

Enrollment
9th of 22
129 · median 76
Started
2017
the only one that year
Phase 2
5 of 25
none open now
Registered
19th of 25
by date

Among the 25 studies in Coronary Artery Disease by AstraZeneca, this one is the 9th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2017, is one of 5 in phase 2, and was the 19th registered.

Coronary Artery Disease

4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 25 studies in Coronary Artery Disease by AstraZeneca is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Coronary Artery Disease by AstraZeneca, or all of them as a file.
02

Study summary

This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries. Approximately 138 CAD patients will be randomized to AZD5718 or placebo (treatment duration 12 weeks).

Read the detailed description

This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries (Denmark, Finland and Sweden).

Patients suitable for the study will be identified and screened for eligibility after being hospitalized for Acute Coronary Syndrome (ACS) (Visit 1) comprising ST Elevation Myocardial Infarction (STEMI) or Non-ST Elevation Myocardial Infarction (non-STEMI). At Visit 1, after signing informed consent, study measurements will take place at days 1, 2, 3 and 5 post ACS, where feasible. It is planned that approximately 138 CAD patients will be randomized to ensure at least 66 evaluable patients receiving AZD5718 Dose B or placebo are included with 12 weeks treatment. For supporting dose selection in future studies, a treatment arm with 28 randomized patients receiving AZD5718 Dose A is included in the study. The study was originally designed to be a 4-week study and was amended to be a 12-week study. Therefore, the total number of patients is greater than required for a 12 weeks study (about 100), since some patients will only have 4 weeks of treatment.

An evaluable patient is defined as a patient with a valid Coronary Flow Velocity Reserve (CFVR) measurement at Visit 2 and one post baseline visit as judged by the CFVR Core lab.

On Day 1 (Visit 2), 7 to 28 days after the ACS event, patients willing to participate in the study will complete the screening procedure and, if eligible, be randomized. Treatment duration will be 12 weeks. During the treatment phase, patients will come in to the clinic for study measurements at 2 weeks (visit 3), 4 weeks (visit 4), 8 weeks (visit 4b) and 12 weeks (visit 4c).

A follow-up visit (Visit 5) will be performed at 4 weeks (±4 days) after last dose in order to ensure safety and well-being of the patients

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females of non-
  • Age ≥18 to ≤75
  • (BMI) ≥18 to ≤35 kg/m2
  • CAD patients, here defined as:

ACS 7-28 days prior to study randomization (ACS defined as STEMI, non STEMI event documented by (ECG), cardiac enzymes [troponin] and angiogram) Provision of signed and dated, written prior to any study specific procedures

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled Type 1 or Type 2 diabetes defined as (HbA1c) Diabetes
  • Control and Complications Trial (DCCT)> 9% or International Federation of Clinical Chemistry (IFCC) >74.9 mmol/mol
  • Patients with atrial fibrillation (chronic or current) or history of ventricular tachycardia requiring therapy for termination, or symptomatic sustained ventricular tachycardia or sick sinus syndrome or Atrioventricular blockage degree 2-3
  • Prior coronary artery by-pass graft (Coronary artery bypass grafting) to Left Anterior Descending artery (LAD)
  • Left ventricle \< 30%
  • Unacceptable level of angina despite maximal medical therapy or unstable angina at entry
  • Canadian Cardiovascular Society (CCS) ≥ 3 (Visit 1 or Visit 2)
  • Stroke within the previous 6 months from ACS or ongoing treatment with Persantin or Asasantin
  • Chronic use of anticoagulants on therapeutic dose (not including thrombosis prophylaxis) during the study
  • Planned additional cardiac intervention (e.g., Percutaneous coronary intervention (PCI), Coronary artery bypass grafting (CABG) within next 6 months
  • (NYHA) class III-IV heart failure or decompensated heart failure at discharge or hospitalization for exacerbation of chronic heart failure within the previous 3 months from ACS
  • Previously known severe renal disease (Chronic Kidney Disease (CKD) stage 4 or 5) or previously known calculated by Cockcroft Gault equation \<30 ml/min*m2
  • Known allergy to adenosine and mannitol, or experience of previous adverse effects of adenosine stress testing.
  • Participation in another interventional clinical study with an pharmaceutical product during the last 3 months also including drug eluting stents.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    AZD5718 Dose A

    AZD5718 Dose A once daily

    Drug: AZD5718

  • Experimental
    AZD5718 Dose B

    AZD5718 Dose B once daily

    Drug: AZD5718

  • Placebo comparator
    Placebo

    Matching placebo once daily

    Drug: Placebo

Interventions

  • Oral dose of AZD5718 (tablet)

  • Oral dose of AZD5718 (tablet)

  • DrugPlacebo

    Matching placebo (tablet)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Creatinine-normalized u-LTE4 at Week 4

    Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine

    Time frame: Baseline and 4 weeks

Secondary outcomes

  1. Change From Baseline in Creatinine-normalized u-LTE4 at Week 12

    Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine

    Time frame: Baseline and 12 weeks

  2. Change From Baseline in CFVR at Week 12

    CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)

    Time frame: Baseline and 12 weeks

  3. Change From Baseline in CFVR at Week 4

    CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)

    Time frame: Baseline and 4 weeks

  4. Summary of Plasma Concentrations of AZD5718

    Time frame: 16 weeks

  5. Change From Baseline in LAD Hypereamic Flow at 4 Weeks

    LAD=Left Anterior Descending

    Time frame: Baseline and 4 weeks

  6. Change From Baseline in LVEF at 4 Weeks

    LVEF=Left Ventricular Ejection Fraction

    Time frame: Baseline and 4 weeks

  7. Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks

    LV=Left Ventricular

    Time frame: Baseline and 4 weeks

  8. Change From Baseline in LV-GLS at Rest at Week 4

    LV-GLS = Left Ventricular Global Longitudinal Strain

    Time frame: Baseline and 4 weeks

  9. Change From Baseline in LV-GCS at Rest at Week 4

    LV-GCS = Left Ventricular Global Circumferential Strain

    Time frame: Baseline and 4 weeks

  10. Change From Baseline in LAD Resting Mean Diastolic Flow Velocity at 4 Weeks

    LAD=Left Anterior Descending

    Time frame: Baseline and 4 weeks

07

Results

Posted Jun 30, 2021

Participant flow

The study was conducted in 3 countries at 9 sites; 3 in Denmark, 2 in Finland and 4 in Sweden.

Participant flow — Overall Study
MilestoneAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Started522552
Completed502451
Not completed211

Outcome measures

PrimaryChange From Baseline in Creatinine-normalized u-LTE4 at Week 4

Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine

Time frame:
Baseline and 4 weeks
Reported as:
Geometric mean · Ratio
Change From Baseline in Creatinine-normalized u-LTE4 at Week 4
RatioAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Change From Baseline in Creatinine-normalized u-LTE4 at Week 40.04 ± 92.550.09 ± 84.321.09 ± 44.38
Statistical analysis
  • AZD5718 (200 mg) vs Placebo · Mixed Models Analysis · p = <0.001 · Ratio: 0.04
  • AZD5718 (50 mg) vs Placebo · Mixed Models Analysis · p = 0.001 · Ratio: 0.08
SecondaryChange From Baseline in Creatinine-normalized u-LTE4 at Week 12

Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine

Time frame:
Baseline and 12 weeks
Reported as:
Geometric mean · Ratio
Change From Baseline in Creatinine-normalized u-LTE4 at Week 12
RatioAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Change From Baseline in Creatinine-normalized u-LTE4 at Week 120.04 ± 92.550.09 ± 84.321.09 ± 44.38
Statistical analysis
  • AZD5718 (200 mg) vs Placebo · Mixed Models Analysis · p = <0.001 · Ratio: 0.04
  • AZD5718 (50 mg) vs Placebo · Mixed Models Analysis · p = 0.001 · Ratio: 0.09
SecondaryChange From Baseline in CFVR at Week 12

CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)

Time frame:
Baseline and 12 weeks
Reported as:
Geometric mean · Ratio
Change From Baseline in CFVR at Week 12
RatioAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Change From Baseline in CFVR at Week 120.93 ± 23.640.98 ± 39.531.16 ± 33.46
SecondaryChange From Baseline in CFVR at Week 4

CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)

Time frame:
Baseline and 4 weeks
Reported as:
Geometric mean · Ratio
Change From Baseline in CFVR at Week 4
RatioAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Change From Baseline in CFVR at Week 41.03 ± 28.341.15 ± 31.471.08 ± 33.16
SecondarySummary of Plasma Concentrations of AZD5718
Time frame:
16 weeks
Reported as:
Geometric mean · nmol/L
Summary of Plasma Concentrations of AZD5718
nmol/LAZD5718 (200 mg)AZD5718 (50 mg)
Baseline: 1-8 Hours Post-Dose611.88 ± 234.5047.88 ± 497.86
2 weeks (Visit 3): 20-28 Hours Post-Dose59.36 ± 90.9716.57 ± 127.80
4 weeks (Visit 4): Pre-Dose48.00 ± 68.1711.01 ± 60.70
4 weeks (Visit 4): 0-2 Hours Post-Dose339.28 ± 243.0438.68 ± 159.56
4 weeks (Visit 4): 2-4 Hours Post-Dose919.22 ± 51.26148.64 ± 71.86
4 weeks (Visit 4): 4-8 Hours Post-Dose649.09 ± 49.89105.40 ± 52.16
12 weeks (Visit 4c): Pre-Dose65.39 ± 91.5213.97 ± 88.12
16 weeks (Visit 5) - FUP 1 month0.51 ± 16.390.50 ± 0.00
SecondaryChange From Baseline in LAD Hypereamic Flow at 4 Weeks

LAD=Left Anterior Descending

Time frame:
Baseline and 4 weeks
Reported as:
Mean · m/sec
Change From Baseline in LAD Hypereamic Flow at 4 Weeks
m/secAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Change From Baseline in LAD Hypereamic Flow at 4 Weeks0.02 ± 0.160.04 ± 0.160.03 ± 0.17
SecondaryChange From Baseline in LVEF at 4 Weeks

LVEF=Left Ventricular Ejection Fraction

Time frame:
Baseline and 4 weeks
Reported as:
Mean · percent LVEF
Change From Baseline in LVEF at 4 Weeks
percent LVEFAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Change From Baseline in LVEF at 4 Weeks-0.23 ± 5.302.70 ± 6.390.48 ± 5.00
SecondaryChange From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks

LV=Left Ventricular

Time frame:
Baseline and 4 weeks
Reported as:
Geometric mean · 1/s
Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks
1/sAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks1.02 ± 30.610.98 ± 33.551.03 ± 30.45
SecondaryChange From Baseline in LV-GLS at Rest at Week 4

LV-GLS = Left Ventricular Global Longitudinal Strain

Time frame:
Baseline and 4 weeks
Reported as:
Mean · Percent LV-GLS
Change From Baseline in LV-GLS at Rest at Week 4
Percent LV-GLSAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Change From Baseline in LV-GLS at Rest at Week 4-0.41 ± 3.000.34 ± 2.47-0.63 ± 2.61
SecondaryChange From Baseline in LV-GCS at Rest at Week 4

LV-GCS = Left Ventricular Global Circumferential Strain

Time frame:
Baseline and 4 weeks
Reported as:
Mean · Percent
Change From Baseline in LV-GCS at Rest at Week 4
PercentAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Change From Baseline in LV-GCS at Rest at Week 40.34 ± 7.241.71 ± 5.40-1.88 ± 6.78
SecondaryChange From Baseline in LAD Resting Mean Diastolic Flow Velocity at 4 Weeks

LAD=Left Anterior Descending

Time frame:
Baseline and 4 weeks
Reported as:
Geometric mean · m/sec
Change From Baseline in LAD Resting Mean Diastolic Flow Velocity at 4 Weeks
m/secAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Change From Baseline in LAD Resting Mean Diastolic Flow Velocity at 4 Weeks1.01 ± 23.310.92 ± 23.680.99 ± 20.14

Adverse events

Collected over Treatment period, up to 12 weeks. Non-serious events are listed at a 0.03% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD5718 (200 mg)0/52 (0%)4/52 (7.7%)27/52 (51.9%)
AZD5718 (50 mg)0/25 (0%)3/25 (12%)12/25 (48%)
Placebo0/51 (0%)4/51 (7.8%)22/51 (43.1%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventAZD5718 (200 mg)AZD5718 (50 mg)Placebo
Acute myocardial infarctionCardiac disorders0/521/250/51
Angina pectorisCardiac disorders0/521/250/51
Ventricular fibrillationCardiac disorders0/521/250/51
Pancreatitis acuteGastrointestinal disorders0/521/250/51
Non-cardiac chest painGeneral disorders0/521/250/51
Chest painGeneral disorders2/520/251/51
DyspnoeaRespiratory, thoracic and mediastinal disorders0/520/251/51
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/520/251/51
Pain in extremityMusculoskeletal and connective tissue disorders0/520/251/51
Post procedural sepsisInfections and infestations1/520/250/51
Most frequent other events
Showing 10 of 14
Most frequent other events
EventAZD5718 (200 mg)AZD5718 (50 mg)Placebo
NasopharyngitisInfections and infestations6/524/257/51
DyspnoeaRespiratory, thoracic and mediastinal disorders6/524/257/51
CoughRespiratory, thoracic and mediastinal disorders5/520/251/51
DizzinessNervous system disorders5/522/254/51
DiarrhoeaGastrointestinal disorders2/521/254/51
Alanine aminotransferase increasedInvestigations0/520/254/51
AnaemiaBlood and lymphatic system disorders4/520/252/51
Chest painGeneral disorders3/521/253/51
FatigueGeneral disorders3/521/250/51
MyalgiaMusculoskeletal and connective tissue disorders3/520/251/51

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AZD5718 (200 mg)AZD5718 (50 mg)PlaceboTotal
Mean61.9 ± 8.2161.4 ± 8.1261.1 ± 8.5161.5 ± 8.26
Sex: Female, Male
Sex: Female, Male(Participants)AZD5718 (200 mg)AZD5718 (50 mg)PlaceboTotal
Female701017
Male452541111
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AZD5718 (200 mg)AZD5718 (50 mg)PlaceboTotal
Hispanic or Latino1001
Not Hispanic or Latino512551127
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AZD5718 (200 mg)AZD5718 (50 mg)PlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White522550127
More than one race0000
Unknown or Not Reported0000
08

Study locations

9 sites
  • Research Site
    Aarhus, 8200, Denmark
  • Research Site
    Frederiksberg, 2000, Denmark
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    Kuopio, 70210, Finland
  • Research Site
    Turku, 20520, Finland
  • Research Site
    Göteborg, 413 45, Sweden
  • Research Site
    Lund, 222 42, Sweden
  • Research Site
    Stockholm, 171 76, Sweden
  • Research Site
    Uppsala, 75185, Sweden
09

References and documents

Publications

  • Prescott E, Angeras O, Erlinge D, Grove EL, Hedman M, Jensen LO, Pernow J, Saraste A, Akerblom A, Svedlund S, Rudvik A, Knochel J, Lindstedt EL, Garkaviy P, Gan LM, Gabrielsen A. Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study. Int J Cardiol. 2022 Oct 15;365:34-40. doi: 10.1016/j.ijcard.2022.07.016. Epub 2022 Jul 14. PubMed 35842004 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Apr 2020, 29 months.

Results were first posted in Jun 2021, 1 year 2 months after primary completion.

Of 26 industry-sponsored phase 2 interventional studies under Coronary Artery Disease, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 29. This study's 29 months is above that.

Counting every sponsor, half of 55 studies reached it within 28 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2017
First posted
Oct 23, 2017
StartActual
Oct 30, 2017
Primary completionActual
Apr 8, 2020
CompletionActual
Apr 8, 2020
Results first posted
Jun 30, 2021
Last update
Jun 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03317002
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 23, 2017
Start date
Oct 30, 2017
Primary completion
Apr 8, 2020
Completion
Apr 8, 2020
Results posted
Jun 30, 2021
Last update
Jun 30, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD5718

Start the discussion